Atlas Trials

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Clinical trial NCT05342636 · COMPLETED

Trial details

NCT number
NCT05342636
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma (ESCC)
Start date
2022-07-27
Primary completion
2025-12-05
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.